Abstract:Purpose: The changed gene-expression profiles of breast cancer under neoadjuvant chemotherapy (NCT) have been described. However, it remains unclear whether chemotherapy affects somatic mutation status in breast cancer. We investigated the influence of paclitaxel-based chemotherapy on somatic mutations in tumor tissues from patients with breast cancer. Patients and Methods: Samples were derived from two cohorts: first, 296 patients who underwent paclitaxel-based NCT with matched pre- and post-chemotherapy tumor tissues; second, 81 patients who underwent paclitaxel-based chemotherapy with pre-chemotherapy tumor tissues. First, we performed whole exome sequencing (WES) to examine the exomes (100-fold coverage) of two paired basal-like breast cancer samples (pre-treatment tumor biopsies and post-treatment tumors). Shift in somatic mutation status was validated by Sanger sequencing and analyzed in an extension cohort of 296 patients. Furthermore, we performed microdissection and genetic heterogeneity analysis for samples from 81 patients who underwent paclitaxel-based chemotherapy. Somatic mutation status was determined to reveal potential impact of paclitaxel-based chemotherapy on mutation status. Results: Compared with post-treatment biopsies, the analysis of WES data identified and validated TP53 and PIK3CA — as significantly mutated genes in pre-treatment tumors with a mutation frequency of approximately 10% in an independent extension cohort of 296 paired samples of different molecular subtypes. Somatic mutations of TP53 or PIK3CA were detected in 24.3% of the pre-chemotherapy tumor samples (35 of 296 for TP53 , 32 of 296 for PIK3CA , 5 of 296 for both genes, respectively) but in only 12.2% of the post-chemotherapy tumor samples (18 of 296 for TP53 , 16 of 296 for PIK3CA , 2 of 296 for both genes, respectively). The decrease in mutation rate was statistically significant ( P < 0.001). Patients with TP53 / PIK3CA mutations switched from positive to negative after chemotherapy had better partial response than patients with no change or with a reverse change ( P = .008). Furthermore, patients with TP53 / PIK3CA mutations switched from positive to negative had improved disease-free survival ( P = 0.018) and improved overall survival ( P = 0.032) relative to patients with no change or with a reverse change. In the second cohort, 18.5% of the tumors (15 of 81) showed intratumoral heterogeneity of TP53 or PIK3CA somatic mutations, whereas 81.5% (66 of 81) were homogeneous, either with mutations of certain genes or not. Conclusion: Our data reveal the novel concept that significant evolution might occur during chemotherapy. Chemotherapy may reduce somatic mutation frequency in patients with breast cancer, likely the result of a preferential response of highly fit sub-clones without mutations of certain genes. In addition, the identification of somatic mutations of TP53 and PIK3CA as biomarkers for prediction of treatment response and prognosis might help us optimize choice for sequential therapy and improve patients’ survival. KEY WORDS : Exome sequencing; TP53 ; PIK3CA ; neoadjuvant chemotherapy; breast cancer. Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr S4-05.

Co-mutation of TP53 and PIK3CA in residual disease after neoadjuvant chemotherapy is associated with poor survival in breast cancer

Concomitant PIK3CA and TP53 Mutations in Breast Cancer: An Analysis of Clinicopathologic and Mutational Features, Neoadjuvant Therapeutic Response, and Prognosis

Favorable Prognostic Impact in Loss of Tp53 and Pik3ca Mutations after Neoadjuvant Chemotherapy in Breast Cancer

Supplementary Figures 1 - 12, Tables 1 - 5 from Favorable Prognostic Impact in Loss of <i>tp53</i> and <i>pik3ca</i> Mutations after Neoadjuvant Chemotherapy in Breast Cancer

The clinical features and prognostic implications of the co-mutated TP53 gene in advanced non-small cell lung cancer

PIK3CA and TP53 Mutations Predict Overall Survival of Stage II/III Colorectal Cancer Patients.

Plasma PIK 3 CA Ctdna Specific Mutation Detected by Next Generation Sequencing is Associated with Clinical Outcome in Advanced Breast Cancer

Association of PIK3CA mutation with outcomes in HER2-positive breast cancer treated with anti-HER2 therapy: A meta-analysis and bioinformatic analysis of TCGA‐BRCA data

PIK3CAmutations and Their Response to Neoadjuvant Treatment in Early Breast Cancer: A Systematic Review and Meta-Analysis

Prevalence and Clinical Impact of TP53 Germline Mutations in Chinese Women with Breast Cancer

Cmar_a_298729 3303..3316

Abstract PO3-08-10: Somatic Mutations of a Multigene Panel in Chinese HER2-positive Patients Undergoing Neoadjuvant Therapy and Impact on Prognosis Based on TP53 Status:A Single-Institution Retrospective Cohort

PIK3CA mutation confers resistance to chemotherapy in triple-negative breast cancer by inhibiting apoptosis and activating the PI3K/AKT/mTOR signaling pathway

Supplementary Figures S1-6 from Association of PIK3CA Mutation Status Before and after Neoadjuvant Chemotherapy with Response to Chemotherapy in Women with Breast Cancer

PIK3CA Mutations Define Favorable Prognostic Biomarkers in Operable Breast Cancer: a Systematic Review and Meta-Analysis

TP53 /KRAS Co-Mutations Create Divergent Prognosis Signatures in Intrahepatic Cholangiocarcinoma

Abstract S4-05: Exome sequencing identifies shift in TP53 and PIK3CA mutation status after paclitaxel-based neoadjuvant chemotherapy in breast cancer

PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup.

The Study of PIK3CA Hotspot Mutations and Co-Occurring with EGFR, KRAS, and TP53 Mutations in Non-Small Cell Lung Cancer

The role of distinct co-mutation patterns with TP53 mutation in immunotherapy for NSCLC

P1.02-045 PIK3CA Mutations in Chinese Patients with Non-Small-Cell Lung Cancer